Patient Information	Specimen Information	Client Information
██████████████████ ████████ ███ ██████ ████ █ ██████ █████ ████ ██████████ Patient ID: NG	Specimen: ████████ ████████████████ ████ ████████████ ████ ████████████ ████ ████████████	Client #: 97515676　MAIL992 SCHWEIG, SUNJYA CCFM-CLIENT BILL ONLY Attn: PATIENT CARE COORDINATOR 2414 ASHBY AVE STE 201 BERKELEY, CA 94705-2063

Test Name	In Range	Out Of Range	Reference Range	Lab
HS CRP	1.3		mg/L	EN

Average relative cardiovascular risk according to
AHA/CDC guidelines.

For ages >17 Years:
hs-CRP mg/L　Risk According to AHA/CDC Guidelines
<1.0　　　　 Lower relative cardiovascular risk.
1.0-3.0　　　Average relative cardiovascular risk.
3.1-10.0　　 Higher relative cardiovascular risk.
　　　　　　 Consider retesting in 1 to 2 weeks to
　　　　　　 exclude a benign transient elevation
　　　　　　 in the baseline CRP value secondary
　　　　　　 to infection or inflammation.
>10.0　　　　Persistent elevation, upon retesting,
　　　　　　 may be associated with infection and
　　　　　　 inflammation.

Test Name	In Range	Out Of Range	Reference Range	Lab
GLUCOSE	82		65-99 mg/dL	UL

Fasting reference interval

Test Name	In Range	Out Of Range	Reference Range	Lab
HEMOGLOBIN A1c	5.1		<5.7 % of total Hgb	UL

For the purpose of screening for the presence of
diabetes:

<5.7%　　　 Consistent with the absence of diabetes
5.7-6.4%　　Consistent with increased risk for diabetes
　　　　　　 (prediabetes)
> or =6.5%　Consistent with diabetes

This assay result is consistent with a decreased risk
of diabetes.

Currently, no consensus exists regarding use of
hemoglobin A1c for diagnosis of diabetes in children.

According to American Diabetes Association (ADA)
guidelines, hemoglobin A1c <7.0% represents optimal
control in non-pregnant diabetic patients. Different
metrics may apply to specific patient populations.
Standards of Medical Care in Diabetes(ADA).

Test Name	In Range	Out Of Range	Reference Range	Lab
URIC ACID	4.2		4.0-8.0 mg/dL	UL

Therapeutic target for gout patients: <6.0 mg/dL

Test Name	In Range	Out Of Range	Reference Range	Lab
LD	188		100-220 U/L	UL
GGT	17		3-90 U/L	UL
TSH	1.72		0.40-4.50 mIU/L	UL
CBC (INCLUDES DIFF/PLT)				UL
WHITE BLOOD CELL COUNT	5.9		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	5.07		4.20-5.80 Million/uL	

Patient Information	Specimen Information	Client Information
████████████████ ████████ ████ ████ █ ████████ Patient ID: NG	Specimen: ████████ █████ █████████████ █████ █████████████ █████ █████████████	Client #: 97515676 SCHWEIG, SUNJYA

Test Name	In Range	Out Of Range	Reference Range	Lab
HEMOGLOBIN	14.7		13.2-17.1 g/dL	
HEMATOCRIT	44.8		38.5-50.0 %	
MCV	88.4		80.0-100.0 fL	
MCH	29.0		27.0-33.0 pg	
MCHC	32.8		32.0-36.0 g/dL	
RDW	12.4		11.0-15.0 %	
PLATELET COUNT	194		140-400 Thousand/uL	
MPV	11.0		7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	3457		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1611		850-3900 cells/uL	
ABSOLUTE MONOCYTES	584		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	218		15-500 cells/uL	
ABSOLUTE BASOPHILS	30		0-200 cells/uL	
NEUTROPHILS	58.6		%	
LYMPHOCYTES	27.3		%	
MONOCYTES	9.9		%	
EOSINOPHILS	3.7		%	
BASOPHILS	0.5		%	
IRON AND TOTAL IRON BINDING CAPACITY				UL
IRON, TOTAL	128		50-180 mcg/dL	
IRON BINDING CAPACITY	334		250-425 mcg/dL (calc)	
% SATURATION	38		15-60 % (calc)	
FERRITIN	231		20-345 ng/mL	UL
VITAMIN B12	615		200-1100 pg/mL	UL

Patient Information	Specimen Information	Client Information
▓▓▓▓▓▓▓▓▓▓▓▓▓▓ ▓▓▓▓▓▓ ▓▓▓▓ ▓▓▓ ▓ ▓▓▓▓ Patient ID: NG	Specimen: ▓▓▓▓ ▓▓▓ ▓▓▓▓▓▓▓ ▓▓▓ ▓▓▓▓▓▓▓ ▓▓▓ ▓▓▓▓▓▓▓	Client #: 97515676 SCHWEIG, SUNJYA

Cardio IQ®

| Test Name	Units	Result and Risk Category			Result from	Risk Category Ranges		
		Optimal	Moderate	High		Optimal	Moderate	High
Lipoprotein Subfractions								Lab: EZ
LDL PARTICLE NUMBER	nmol/L	1062				<1138	1138-1409	>1409
LDL SMALL	nmol/L	141				<142	142-219	>219
LDL MEDIUM	nmol/L	205				<215	215-301	>301
HDL LARGE	nmol/L		5597			>6729	6729-5353	<5353

For details on reference ranges please refer to the reference range/comment section of the report.

4myheart Diet & Exercise Coaching Program: Need help achieving and maintaining an optimal weight? Managing stress? Trying to improve physical fitness levels? The 4myheart program provides support and personalized lifestyle guidance to help improve heart health. Please talk to your provider, visit 4myheart.com or call 1-800-432-7889 opt 2 to learn more.

Medical Information For Healthcare Providers: If you have any questions about any of the tests in our Cardio IQ offering, please call 1-800-432-7889 opt 3 to speak to a clinical liaison. For frequently asked questions, you can also visit us at http://education.questdiagnostics.com/faq/FAQ134

Patient Information	Specimen Information	Client Information
▮▮▮▮▮▮▮▮▮▮ ▮▮▮▮ ▮▮▮▮ ▮▮ ▮▮▮▮ Patient ID: NG	Specimen: ▮▮▮▮ ▮▮▮ ▮▮▮▮▮ ▮▮▮ ▮▮▮▮▮ ▮▮▮ ▮▮▮▮▮	Client #: 97515676 SCHWEIG, SUNJYA

LIPID SUBCLASS DETAIL FROM ION MOBILITY

Test Name	Units	Result and Risk Category			Result from	Risk Category Ranges		
		Optimal	Moderate	High		Optimal	Moderate	High
Lipoprotein Subfractions								Lab: EZ
LDL PATTERN	Pattern	A				A	N/A	B
LDL PEAK SIZE	Angstrom		222.3			>222.9	222.9-217.4	<217.4

Patient Information	Specimen Information	Client Information
████████████████ ██████ ██████ █████ █ ██████ ████ NG	Specimen: ██████ ████ ████████████ ████ ████████████ ████ ████████████	Client #: 97515676 SCHWEIG, SUNJYA

Reference Range/Comments

| Analyte Name	Reference Range	Comments
LDL PARTICLE NUMBER	732-2035 nmol/L	Risk: Optimal <1138; Moderate 1138-1409; High >1409
LDL SMALL	85-473 nmol/L	Risk: Optimal <142; Moderate 142-219; High >219
LDL MEDIUM	122-498 nmol/L	Risk: Optimal <215; Moderate 215-301; High >301
HDL LARGE	3382-9376 nmol/L	Risk: Optimal >6729; Moderate 6729-5353; High <5353
LDL PATTERN	A Pattern	Risk: Optimal Pattern A; High Pattern B
LDL PEAK SIZE	> OR = 217.4 Angstrom	Risk: Optimal >222.9; Moderate 222.9-217.4; High <217.4 Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on adult U.S. reference population. Association between lipoprotein subfractions and cardiovascular events is based on Musunuru et al. ATVB. 2009;29:1975. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PERFORMING SITE:

EN   QUEST DIAGNOSTICS-WEST HILLS, 8401 FALLBROOK AVENUE, WEST HILLS, CA 91304-3226 Laboratory Director: TAB TOOCHINDA,MD, CLIA: 05D0642827
EZ   QUEST DIAGNOSTICS/NICHOLS SJC, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: IRINA MARAMICA,MD,PHD,MBA, CLIA: 05D0643352
UL   QUEST DIAGNOSTICS SACRAMENTO, 3714 NORTHGATE BLVD, SACRAMENTO, CA 95834-1617 Laboratory Director: M. ROSE AKIN, M.D., FCAP, CLIA: 05D0644209

Patient Information	Specimen Information	Client Information
		Client #: 97515676 MAIL992
		SCHWEIG, SUNJYA
		CCFM-CLIENT BILL ONLY
	:	Attn: PATIENT CARE
		COORDINATOR
		2414 ASHBY AVE STE 201
	(* A Copy Sent To)	BERKELEY, CA 94705-2063

Test Name	In Range	Out Of Range	Reference Range	Lab
INSULIN	4.9		2.0–19.6 uIU/mL	EN

    This insulin assay shows strong cross-reactivity for
some insulin analogs (lispro, aspart, and glargine)
and much lower cross-reactivity with others (detemir,
glulisine).

PERFORMING SITE:

EN   QUEST DIAGNOSTICS-WEST HILLS, 8401 FALLBROOK AVENUE, WEST HILLS, CA 91304-3226 Laboratory Director: TAB TOOCHINDA,MD, CLIA: 05D0642827

* Copy To Client: OPEN MEDICINE